- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 02.04. | British biotech CellCentric expands to Boston with plans to grow into late-stage clinical development | ||
| 02.04. | FDA's Chief Medical Officer Hilary Marston is out amid mass layoffs | ||
| 02.04. | Edgewise claims heart valve pressure benefits in phase 2 trial for potential Camzyos rival | ||
| 02.04. | Sanofi taps Nurix for pipeline nourishment once again, picking up autoimmune degrader for $15M | ||
| 02.04. | Patient suffers side effect in Cabaletta autoimmune CAR-T trial, but analysts unfazed | ||
| 01.04. | Flagship-backed Sail Biomedicines lays off staff following review of organizational structure | ||
| 01.04. | After Eric Green's exit, new leader of NIH's genome research institute put on administrative leave: Stat | ||
| 01.04. | Cerevance fails phase 2 trial in early, untreated Parkinson's | ||
| 01.04. | Pfizer, Flagship tap Valo Health for autoimmune offshoot of multibillion-dollar collab | ||
| 01.04. | Merck Group pays $85M to nab global rights for Abbisko's rare tumor drug after phase 3 win | ||
| 01.04. | Carisma winds down operations, lays off 95% of remaining staff | ||
| 01.04. | Lundbeck ends subcutaneous migraine cohort after futility review, pivots to IV formulation | ||
| 01.04. | Cancer biotech Inspirna winding down as its odyssey in microRNA comes to an end | ||
| 31.03. | Sanofi snags GSK's Chris Corsico to serve as global head of development | ||
| 31.03. | Corcept's investigational oral therapy cuts ovarian cancer progression by 30%, teeing up FDA filing | ||
| 31.03. | Apollomics hands Asia rights to its lead c-MET inhibitor to Taiwan's LaunXP in $60M deal | ||
| 31.03. | Alphabet's AI biotech Isomorphic Labs hauls in $600M to power next-gen drug design model | ||
| 31.03. | BiomX's bacteria-killing virus reduces diabetic bone ulcers in midstage test | ||
| 31.03. | Transcend rises above threshold for success, linking MDMA analog to PTSD improvements in phase 2 | ||
| 31.03. | Opthea scraps wet AMD program after eye drug loses out to Lucentis in latest phase 3 fail | ||
| 31.03. | Lilly links lepodisiran to durably lower lipoprotein in phase 2, providing edge over Amgen and Novartis | ||
| 31.03. | Vertex abandons islet cell-device combo after failing to improve diabetes biomarker | ||
| 28.03. | Relmada reconsiders phase 2 plans to test magic mushroom extract for obesity | ||
| 28.03. | BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific | ||
| 28.03. | Novo inks $1B biobucks Lexicon obesity deal after seeing preclinical prospect shine with semaglutide |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
